入院喘患者吸入性皮质类固醇反应的预测模型:对精准医学的影响
Dong Liu1, Luna Zhao2, Ye Liu2
1Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Shihezi University, Shihezi, China.
Journal of thoracic disease
|October 29, 2025
概括
最初用吸入性皮质类固醇 (ICS) 治疗的喘患者可能需要全身性皮质类固醇 (SCS). 一个新的模型预测了ICS治疗升级,识别了潜在的SCS过度使用,并改善了喘管理.
科学领域:
- 肺部病理学 肺部病理学
- 医疗信息学 医疗信息学
- 药理学 药理学是指药理学的学科.
背景情况:
- 吸入性皮质类固醇 (ICS) 是第一线喘治疗,但患者的反应有所不同,需要系统性皮质类固醇 (SCS).
- 早期识别可能需要治疗升级的患者对于优化喘管理至关重要.
- 由于相关的成本和副作用,SCS的潜在过度使用需要调查.
研究的目的:
- 开发一种早期预测模型,用于喘患者吸入性皮质类固醇 (ICS) 的反应.
- 确定与需要治疗升级到全身皮质类固醇 (SCS) 相关的临床特征.
- 提供有关系统性皮质类固醇 (SCS) 潜在过度使用的证据.
主要方法:
- 利用了从5463名喘患者 (≥12年) 获得的数据,这些患者在2006-2022年期间接受了ICS治疗.
- 采用机器学习算法,包括随机森林,开发和验证SCS升级的预测模型.
- 应用因果推断技术来评估SCS过度使用.
主要成果:
- 19.9%的患者需要升级到SCS.
- 使用40个预测因素的随机森林模型实现了0.7483 (内部) 和0.6941 (外部验证) 的AUC,用于预测SCS需求.
- 关键预测指标包括血中氨基细胞计数,中性细胞计数,年龄和淋巴细胞计数. 在患者中发现了潜在的SCS过度使用,结果类似,但成本更高.
结论:
- 一个经过验证的预测模型可以帮助早期识别需要SCS的喘患者.
- 该模型为住院患者提供了一个具有成本效益的工具.
- 研究结果表明,有策略可以减轻在喘护理中SCS的潜在过度使用.
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
Inhaled Medications
728
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
728
COPD: Management Using Bronchodilators and Corticosteroids
719
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
719
Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Asthma-II: Pathophysiology and Classification
4.1K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.1K
Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K


